DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for progeroid syndrome — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleProgeroid syndrome maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for progeroid syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
farnesyltransferase, CAAX box, subunit alpha (FNTA) — FNTA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet fardrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2H6F · 1.5 Å · ligand FARNESYL (FAR). Experimental structure, not a prediction.
What the evidence adds up to
A 2014 transgenic mouse study expressed the most common Hutchinson-Gilford progeria syndrome mutation (LMNA c.1824C>T) in brain, skin, bone and heart. After 70 weeks of expression, neuronal nuclei showed severe distortion with multiple lobulations and irregular extensions. Despite these structural nuclear abnormalities in hippocampal neurons, gene expression changes after 63 weeks were negligible. Behavioural analysis and neurogenesis assays following long-term expression did not reveal significant pathology. The authors concluded that certain tissues appear protected from functional deleterious effects of progerin.
A 1994 report on neonatal progeroid syndrome (Wiedemann-Rautenstrauch) described diagnostic criteria including intrauterine and postnatal growth failure, hydrocephalic appearance, prominent scalp veins, old-looking face, absence of subcutaneous fat, and neonatal teeth. Nine cases had been reported at that time, predominantly diagnosed in infancy. The syndrome was assigned to autosomal recessive inheritance. One patient presented in 1977 under the diagnosis progeria was then 16 years old; she had developed considerable ataxic movement disturbance alongside psychomotor retardation. A metabolic change in proteoglycan that had been notable in infancy was no longer detectable.
A 1997 report described father-to-son transmission of a progeroid syndrome with facial anomalies, sparse subcutaneous fat, and hand anomalies including syndactyly, camptodactyly, and finger deviation. Mild mental retardation, microcephaly, and congenital heart defect were found only in the son. The authors stated this syndrome had not been described previously.
What remains missing is any clinical trial testing a drug in any of these progeroid syndromes. The mouse study suggests that even severe nuclear abnormalities in the brain may not produce functional deficits, which complicates the search for a measurable brain outcome in a trial. No abstract reports a drug intervention, a survival benefit, or a response rate. The rarity of these conditions — nine reported cases of neonatal progeroid syndrome as of 1994 — means any future trial would need multi-centre collaboration and a carefully chosen primary endpoint.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Human Molecular Genetics · 2014 · 40 citations · open access
Expression of progerin in aging mouse brains reveals structural nuclear abnormalities without detectible significant alterations in gene expression, hippocampal stem cells or behavior
AbstractHutchinson-Gilford progeria syndrome (HGPS) is a segmental progeroid syndrome with multiple features suggestive of premature accelerated aging. Accumulation of progerin is thought to underlie the pathophysiology of HGPS. However, despite ubiquitous expression of lamin A in all differentiated cells, the HGPS mutation results in organ-specific defects. For example, bone and skin are strongly affected by HGPS, while the brain appears to be unaffected. There are no definite explanations as to the variable sensitivity to progeria disease among different organs. In addition, low levels of progerin have also been found in several tissues from normal individuals, but it is not clear if low levels of progerin contribute to the aging of the brain. In an attempt to clarify the origin of this phenomenon, we have developed an inducible transgenic mouse model with expression of the most common HGPS mutation in brain, skin, bone and heart to investigate how the mutation affects these organs. Ultrastructural analysis of neuronal nuclei after 70 weeks of expression of the LMNA c.1824C>T mutation showed severe distortion with multiple lobulations and irregular extensions. Despite severe distortions in the nuclei of hippocampal neurons of HGPS animals, there were only negligible changes in gene expression after 63 weeks of transgenic expression. Behavioral analysis and neurogenesis assays, following long-term expression of the HGPS mutation, did not reveal significant pathology. Our results suggest that certain tissues are protected from functional deleterious effects of progerin.
AbstractThe diagnostic criteria of the neonatal progeroid syndrome (NPS) are: intrauterine and postnatal growth failure, hydrocephalic appearance, prominent scalp veins, old-looking face, absence of subcutaneous fat and neonatal teeth. Until now altogether nine cases have been reported, which were predominant diagnosed in infant age. The NPS is in general assigned to the autosomal recessive trait. With increasing age the outward appearance stays unchanged. The in 1977 under diagnose progeria presented patient is now 16 years old. With her a considerable atactic movement disturbance developed next to a psychomotoric retardation. The change in metabolism of proteoglycane that was remarkable in infant age is now no longer provable.
American Journal of Medical Genetics · 1997 · 7 citations
Progeroid syndrome with characteristic facial appearance and hand anomalies in father and son
AbstractWe report on the father-to-son transmission of a progeroid syndrome characterized by facial anomalies, sparse subcutaneous fat, and hand anomalies including syndactyly, camptodactyly, and finger deviation. Mild mental retardation, microcephaly, and congenital heart defect were found only in the son. To our knowledge, this syndrome has not been described previously.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
